Immunovant, Inc. (IMVT) — Analyst outlook / Analyst consensus target is. Based on 23 analyst ratings, the consensus is bullish — 18 Buy, 4 Hold, 1 Sell.
The consensus price target is $35.67 (low: $16.00, high: $50.00), representing an upside of 34.4% from the current price $26.55.
Analysts estimate Earnings Per Share (EPS) of $-2.81 and revenue of $0.03B for the next fiscal year.
Earnings Per Share (EPS) track record: 2025: actual $-2.73 vs est $-2.81 (beat +2.7%). Analyst accuracy: 97%.
IMVT Stock — 12-Month Price Forecast
$35.67
▲ +34.35% Upside
Average Price Target
Based on 23 Wall Street analysts offering 12-month price targets for Immunovant, Inc., the average price target is $35.67, with a high forecast of $50.00, and a low forecast of $16.00.
The average price target represents a +34.35% change from the last price of $26.55.
Highest Price Target
$50.00
Average Price Target
$35.67
Lowest Price Target
$16.00
IMVT Analyst Ratings
Buy
Based on 23 analysts giving stock ratings to Immunovant, Inc. in the past 3 months
EPS Estimates — IMVT
97%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2025
Actual –$2.73
vs Est –$2.81
▲ 2.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — IMVT
Revenue Trend
Analysts expect stable revenue going forward.
